Evidence map›Paper›PMID 42396941›Full record

ArticleJournal of immunology research2026

Anti-MAG Polyneuropathy: Characterization of the Monoclonal Gammopathy and Clonal B-Cell Population.

Geir Erland Tjønnfjord, Liv Toril N Osnes, Signe Spetalen, Ulla Haave, Trine H Popperud, Angelina H Maniaol, Ingunn Østlie, Livia Bajelan, Lars Henrik D Hamnvik, Kristo Marvyin and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Geir Erland TjønnfjordDepartment of Haematology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.ORCID https://orcid.org/0000-0002-7757-4091
Liv Toril N OsnesDepartment of Immunology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
Signe SpetalenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway, uio.no.
Ulla HaaveInstitute of Clinical Medicine, University of Oslo, Oslo, Norway, uio.no.ORCID https://orcid.org/0000-0003-2097-4278
Trine H PopperudDepartment of Neurology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
Angelina H ManiaolDepartment of Neurology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
Ingunn ØstlieDepartment of Pathology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
Livia BajelanDepartment of Immunology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
Lars Henrik D HamnvikDepartment of Internal Medicine, Vestre Viken Hospital Trust, Drammen, Norway, vestreviken.no.
Kristo MarvyinDepartment of Hematology, Akershus University Hospital, Lørenskog, Norway, ahus.no.
Dragana MiskovicDepartment of Internal Medicine, Telemark Hospital Trust, Skien, Norway, sthf.no.
Eirik B TjønnfjordDepartment of Haematology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
Kristoffer WinjeDepartment of Internal Medicine, Innlandet Hospital Trust, Gjøvik, Norway, sykehuset-innlandet.no.
Magnus MoksnesCancer and Hematology Center, Vestfold Hospital Trust, Tønsberg, Norway, siv.no.
Tor Henrik A TvedtDepartment of Haematology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
Ann Kristin KvamDepartment of Haematology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
Agnieszka MaleckaDepartment of Haematology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.ORCID https://orcid.org/0000-0002-3381-5981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polyneuropathy due to antibodies to myelin-associated glycoprotein (MAG) is a rare disease with an estimated prevalence of 1 per 100,000. Symptoms start in the sixth or seventh decade of life, presenting sensory polyneuropathy with sensory ataxia, paresthesia, mild motor deficit, and tremor of upper extremities. The neurophysiological features are compatible with length-dependent demyelination. It is caused by monoclonal gammopathy of the IgM type produced by clonal B cells. In recent years the monoclonal anti-CD20 antibody has become the preferred first-line treatment, but with limited efficacy. We identified a cohort of 42 patients diagnosed with anti-MAG polyneuropathy. Clinical data were collected retrospectively, and flow cytometry files and immune histochemistry slides were reassessed. We report that in most cases of anti-MAG polyneuropathy, the monoclonal IgM is kappa-restricted, the B-cell population shows lymphoplasmacytic differentiation, MYD88

Indexed as

B-LymphocytesMyelin-Associated GlycoproteinParaproteinemiasPolyneuropathiesAdultAgedAged, 80 and overAutoantibodiesFemaleHumansImmunoglobulin MMaleMiddle AgedPlasma CellsRetrospective StudiesRituximabAutoantibodiesImmunoglobulin MMyelin-Associated GlycoproteinRituximab

Identifiers

PMID42396941
PMCPMC13329836

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.